News Column

Reports Summarize DNA Vaccines Study Results from J. Yan and Co-Researchers (Protective immunity to H7N9 influenza viruses elicited by synthetic DNA...

July 15, 2014



Reports Summarize DNA Vaccines Study Results from J. Yan and Co-Researchers (Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine)

By a News Reporter-Staff News Editor at Life Science Weekly -- Data detailed on Biotechnology have been presented. According to news reporting originating in Blue Bell, Pennsylvania, by NewsRx journalists, research stated, "Despite an intensive vaccine program influenza infections remain a major health problem, due to the viruses' ability to change its envelope glycoprotein hemagglutinin (HA), through shift and drift, permitting influenza to escape protection induced by current vaccines or natural immunity. Recently a new variant, H7N9, has emerged in China causing global concern."

The news reporters obtained a quote from the research, "First, there have been more than 130 laboratory-confirmed human infections resulting in an alarmingly high death rate (32.3%). Second, genetic changes found in H7N9 appear to be associated with enabling avian influenza viruses to spread more effectively in mammals, thus transmitting infections on a larger scale. Currently, no vaccines or drugs are effectively able to target H7N9. Here, we report the rapid development of a synthetic consensus DNA vaccine (pH7HA) to elicit potent protective immunity against the H7N9 viruses. We show that pH7HA induces broad antibody responses that bind to divergent HAs from multiple new members of the H7N9 family. These antibody responses result in high-titer HAI against H7N9. Simultaneously, this vaccine induces potent polyfunctional effector CD4 and CD8T cell memory responses. Animals vaccinated with pH7HA are completely protected from H7N9 virus infection and any morbidity associated with lethal challenge."

According to the news reporters, the research concluded: "This study establishes that this synthetic consensus DNA vaccine represents a new tool for targeting emerging infection, and more importantly, its design, testing and development into seed stock for vaccine production in a few days in the pandemic setting has significant implications for the rapid deployment of vaccines protecting against emerging infectious diseases."

For more information on this research see: Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. Vaccine, 2014;32(24):2833-42. (Elsevier - www.elsevier.com; Vaccine - www.journals.elsevier.com/vaccine)

Our news correspondents report that additional information may be obtained by contacting J. Yan, Inovio Pharmaceuticals, Inc, 1787 Sentry Parkway West, Building 18, Suite 400, Blue Bell, PA 19422, United States. Additional authors for this research include D.O. Villarreal, T. Racine, J.S. Chu, J.N. Walters, M.P. Morrow, A.S. Khan, N.Y. Sardesai, J.J. Kim, G.P. Kobinger and D.B Weiner (see also Biotechnology).

Keywords for this news article include: Biotechnology, Blue Bell, Viral DNA, Pennsylvania, DNA Research, DNA Vaccines, United States, Synthetic Vaccines, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Life Science Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters